Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia

Wanda L. Salzer(Maine Medical Center), Bernard L. Marini(University of Michigan), Bruce Bostrom(Minnesota West Community & Technical College), Yoav H. Messinger(Children’s Minnesota - St. Paul Hospital), Anthony J. Perissinotti(University of Michigan)

Leukemia & lymphoma/Leukemia and lymphoma

October 18, 2017

10.1080/10428194.2017.1386305

Cited by 108

Related Papers

A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

|Blood|2002|496

Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232

|Journal of Clinical Oncology|2016|384

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232

|Blood|2015|365

Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group

|Blood|2003|361

Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic Leukemia

|New England Journal of Medicine|1987|334